Diagnostic and therapeutic advances in treatment-resistant mood disorders.
B. Blinder,A. Bloom
1996-03-01
Western Journal of Medicine
Abstract:Delirium is a reversible impairment of cognition characterized by disorientation, impaired short-term memory, short attention span, altered perceptions of the environment, abnormal thought processes, inappropriate behavior, fluctuating levels of consciousness, and a worsening of symptoms at night. The last two symptoms are virtually diagnostic of delirium. Several factors usually contribute to delirium in patients, and a multifactorial cause should always be considered. Patients with dementia brain injury and older persons are particularly vulnerable to delirium. The first priority in managing agitation due to delirium is to assess and treat the underlying cause. The immediate management of a patient's dangerous behavior usually requires additional intervention, however. Physical and chemical restraints can be effective in managing severe agitation and lowering the risk of injury to patients and staff. Mildly to moderately agitated patients who are responsive to verbal intervention can usually be managed with a multidisciplinary treatment plan that emphasizes physical and emotional supportive care, structured routines and activities, and the manipulation of environmental stimuli to help orient the patient and improve his or her coping mechanisms. The cornerstone of chemical restraint for agitated patients is a high-potency neuroleptic agent. Haloperidol is most frequently used because of its ease of administration and titration and its reduced anticholinergic effect compared with other neuroleptics. The starting dose for acutely agitated patients can be from 1 to 10 mg, given by intravenous push, depending on the patient's age, size, and degree of agitation. Older patients should be started on lower doses of 1 to 3 mg. If the patient remains agitated, the starting dose should be doubled and readministered every 15 to 20 minutes until agitation is controlled. The patient should be closely monitored for adverse medication effects, including extrapyramidal symptoms, acute dystonia, akathisia, and the development of the neuroleptic malignant syndrome. Akathisia, a feeling of motor restlessness, is often mistaken for increased agitation. Most extrapyramidal symptoms respond to the use of antiparkinsonian agents, such as diphenhydramine, or to benzodiazepines. Several other pharmacologic agents are used to control agitation. The use of benzodiazepines in combination with haloperidol is frequently helpful. Diazepam and lorazepam are easily administered and have a rapid onset of action. Lorazepam is used in patients with compromised liver function. Patients who are agitated during alcohol or sedative withdrawal can be managed with benzodiazepines alone. Aggressive management is recommended to prevent delirium tremens. Narcotic withdrawal and associated agitation should be managed with opioids. Patients who have been taking narcotics or benzodiazepines long term should be carefully tapered to prevent the development of agitation. Other psychotropic agents often used to control agitation and impulsivity include divalproex sodium, carbamazepine, propranolol, and buspirone. Intensive care units are the most frequent setting for the occurrence of severe agitation because of the multiple stressors contributing to delirium and anxiety in patients. These include painful procedures or activities, environmental stimulation from constant noise and light, physical restraints, mechanical ventilation, and an unfamiliar environment. Frequently agitation occurs at the time a patient awakens from anesthetics, narcotics, and sedatives given at the time of admission or a surgical procedure. Inadequate pain control is a frequent contributor to agitation and must be carefully evaluated. A comprehensive treatment plan with good supportive care can minimize the need for physical and chemical restraints.